Scientists have reported a major breakthrough in our understanding of inflammatory bowel disorder. It could lead to more effective treatments for conditions like Crohn's disease, a new study found.

A lthough some health conditions are spoken about with more nuance and understanding than in the past, inflammatory bowel ...

Although several treatment options exist in the management of Crohn's disease, a patient-centered approach is integral amid ...

LGBTQ patients afflicted with inflammatory bowel disease, an autoimmune condition that affects some 2 million to 3 million ...

Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025.

An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...

Researchers sought to determine the prevalence, characteristics, management, and outcomes of difficult-to-treat IBD.

A three-day National Inflammatory Bowel Disease (IBD) Conference and the second roundtable meeting of the BRICS IBD Consortium, being organised by the Vizag Gut Club Association in collaboration with ...

Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...

Advertisement Ulcerative colitis affects over 900,000 Americans and is a form of inflammatory bowel disease (IBD). The exact ...

Pseudopolyps ocurr due to the inflammation related to Crohn's disease or ulcerative colitis. Learn what pseudopolyps on ...